← Oncology Approval Tracker

FDA DECISION ·

Phyrago

dasatinib · Nanocopoeia

FDA approvalNew formulationChronic myeloid leukemia and acute lymphoblastic leukemia
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

An oral dasatinib tablet for adults with newly diagnosed chronic-phase Ph-positive CML, Ph-positive CML resistant or intolerant to prior therapy including imatinib across specified phases, or Ph-positive ALL resistant or intolerant to prior therapy.

LAMPGEN ANALYSIS

Why it matters

The approved presentation adds a dasatinib product with product-specific administration instructions.

What research teams should watch

Confirm the dispensed formulation and use its specific instructions for concomitant medicines, dose and administration.

PRIMARY RECORDS

Sources